Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma.

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma.'. Together they form a unique fingerprint.

Medicine & Life Sciences